BidaskClub upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a sell rating to a hold rating in a report published on Thursday.
ASMB has been the topic of several other reports. Zacks Investment Research downgraded shares of Assembly Biosciences from a buy rating to a hold rating in a report on Monday, January 15th. B. Riley started coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They set a neutral rating and a $35.00 target price on the stock. Jefferies Group raised their target price on shares of Assembly Biosciences to $75.00 and gave the stock a buy rating in a report on Thursday, March 8th. Finally, ValuEngine upgraded shares of Assembly Biosciences from a sell rating to a hold rating in a report on Saturday, February 3rd. Five analysts have rated the stock with a hold rating and one has given a buy rating to the stock. Assembly Biosciences currently has an average rating of Hold and an average target price of $58.00.
Shares of NASDAQ:ASMB opened at $44.83 on Thursday. The company has a market capitalization of $992.26, a P/E ratio of -18.60 and a beta of 0.74. Assembly Biosciences has a fifty-two week low of $18.60 and a fifty-two week high of $67.36.
In other Assembly Biosciences news, Director William R. Ringo sold 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $46.86, for a total transaction of $46,860.00. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Insiders have sold a total of 3,000 shares of company stock worth $152,550 over the last 90 days. Corporate insiders own 19.60% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. Teacher Retirement System of Texas acquired a new stake in Assembly Biosciences during the 4th quarter worth approximately $242,000. MetLife Investment Advisors LLC bought a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $326,000. Virtus Fund Advisers LLC bought a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $361,000. Endurant Capital Management LP bought a new position in shares of Assembly Biosciences during the 4th quarter worth approximately $430,000. Finally, American International Group Inc. grew its stake in shares of Assembly Biosciences by 15.4% during the 4th quarter. American International Group Inc. now owns 10,853 shares of the biopharmaceutical company’s stock worth $491,000 after acquiring an additional 1,450 shares in the last quarter. Hedge funds and other institutional investors own 76.81% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Assembly Biosciences (ASMB) Raised to Hold at BidaskClub” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this article on another site, it was copied illegally and republished in violation of international trademark & copyright law. The original version of this article can be accessed at https://ledgergazette.com/2018/04/15/assembly-biosciences-asmb-raised-to-hold-at-bidaskclub.html.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome in the United States.
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.